Do analysts prefer BNTC or AIFC?

Benitec Biopharma presently has a consensus price target of $27.00, indicating a potential upside of 143.24%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Benitec Biopharma is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, BNTC or AIFC?

Benitec Biopharma has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma $80K 4,766.06 -$37.92M -$1.14 N/A ALT5 Sigma $24.84M 3.91 -$344.51M N/A N/A

Does the media refer more to BNTC or AIFC?

In the previous week, ALT5 Sigma had 3 more articles in the media than Benitec Biopharma. MarketBeat recorded 4 mentions for ALT5 Sigma and 1 mentions for Benitec Biopharma. ALT5 Sigma's average media sentiment score of 0.38 beat Benitec Biopharma's score of 0.33 indicating that ALT5 Sigma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SOPH or AIFC?

SOPHiA GENETICS presently has a consensus price target of $7.50, indicating a potential upside of 52.13%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, equities research analysts clearly believe SOPHiA GENETICS is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, SOPH or AIFC?

SOPHiA GENETICS has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SOPHiA GENETICS $77.27M 4.37 -$79M -$0.52 N/A ALT5 Sigma $24.84M 3.91 -$344.51M N/A N/A

Does the media favor SOPH or AIFC?

In the previous week, SOPHiA GENETICS had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 6 mentions for SOPHiA GENETICS and 4 mentions for ALT5 Sigma. SOPHiA GENETICS's average media sentiment score of 0.39 beat ALT5 Sigma's score of 0.38 indicating that SOPHiA GENETICS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AIFC or LRMR?

Larimar Therapeutics has a consensus price target of $15.29, indicating a potential upside of 349.58%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09

Which has stronger valuation and earnings, AIFC or LRMR?

Larimar Therapeutics has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.91 -$344.51M N/A N/A Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A

Does the media favor AIFC or LRMR?

In the previous week, ALT5 Sigma had 3 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for ALT5 Sigma and 1 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.87 beat ALT5 Sigma's score of 0.38 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend AIFC or PBYI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, AIFC or PBYI?

Puma Biotechnology has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.91 -$344.51M N/A N/A Puma Biotechnology $228.40M 1.60 $31.11M $0.48 14.94

Does the media favor AIFC or PBYI?

In the previous week, Puma Biotechnology had 4 more articles in the media than ALT5 Sigma. MarketBeat recorded 8 mentions for Puma Biotechnology and 4 mentions for ALT5 Sigma. Puma Biotechnology's average media sentiment score of 0.96 beat ALT5 Sigma's score of 0.38 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AIFC or XFOR?

X4 Pharmaceuticals has a consensus target price of $9.38, suggesting a potential upside of 132.05%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings & valuation, AIFC or XFOR?

X4 Pharmaceuticals has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.91 -$344.51M N/A N/A X4 Pharmaceuticals $35.11M 10.85 -$79.20M -$4.54 N/A

ALT5 Sigma (AIFC) Competitors

$0.69 -0.04 (-4.92%)

As of 04:00 PM Eastern

Compare

AIFC vs. BNTC, SOPH, LRMR, PBYI, and XFOR

Should you buy ALT5 Sigma stock or one of its competitors? MarketBeat compares ALT5 Sigma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALT5 Sigma include Benitec Biopharma (BNTC), SOPHiA GENETICS (SOPH), Larimar Therapeutics (LRMR), Puma Biotechnology (PBYI), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry.

How does ALT5 Sigma compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Benitec Biopharma has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	4,766.06	-$37.92M	-$1.14	N/A
ALT5 Sigma	$24.84M	3.91	-$344.51M	N/A	N/A

Benitec Biopharma has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Benitec Biopharma's return on equity of -34.82% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Benitec Biopharma presently has a consensus price target of $27.00, indicating a potential upside of 143.24%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Benitec Biopharma is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Benitec Biopharma has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

In the previous week, ALT5 Sigma had 3 more articles in the media than Benitec Biopharma. MarketBeat recorded 4 mentions for ALT5 Sigma and 1 mentions for Benitec Biopharma. ALT5 Sigma's average media sentiment score of 0.38 beat Benitec Biopharma's score of 0.33 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Benitec Biopharma beats ALT5 Sigma on 10 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to SOPHiA GENETICS?

SOPHiA GENETICS (NASDAQ:SOPH) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, SOPHiA GENETICS had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 6 mentions for SOPHiA GENETICS and 4 mentions for ALT5 Sigma. SOPHiA GENETICS's average media sentiment score of 0.39 beat ALT5 Sigma's score of 0.38 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SOPHiA GENETICS presently has a consensus price target of $7.50, indicating a potential upside of 52.13%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, equities research analysts clearly believe SOPHiA GENETICS is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

SOPHiA GENETICS has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	4.37	-$79M	-$0.52	N/A
ALT5 Sigma	$24.84M	3.91	-$344.51M	N/A	N/A

SOPHiA GENETICS has a net margin of -44.48% compared to ALT5 Sigma's net margin of -2,483.94%. SOPHiA GENETICS's return on equity of -62.74% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Summary

SOPHiA GENETICS beats ALT5 Sigma on 13 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Larimar Therapeutics?

ALT5 Sigma (NASDAQ:AIFC) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Larimar Therapeutics has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.91	-$344.51M	N/A	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

In the previous week, ALT5 Sigma had 3 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for ALT5 Sigma and 1 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.87 beat ALT5 Sigma's score of 0.38 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ALT5 Sigma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Larimar Therapeutics has a consensus price target of $15.29, indicating a potential upside of 349.58%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Larimar Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Larimar Therapeutics	N/A	-134.14%	-96.00%

Summary

Larimar Therapeutics beats ALT5 Sigma on 9 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Puma Biotechnology?

ALT5 Sigma (NASDAQ:AIFC) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has a net margin of 10.69% compared to ALT5 Sigma's net margin of -2,483.94%. Puma Biotechnology's return on equity of 20.30% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Puma Biotechnology	10.69%	20.30%	12.05%

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Puma Biotechnology has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.91	-$344.51M	N/A	N/A
Puma Biotechnology	$228.40M	1.60	$31.11M	$0.48	14.94

In the previous week, Puma Biotechnology had 4 more articles in the media than ALT5 Sigma. MarketBeat recorded 8 mentions for Puma Biotechnology and 4 mentions for ALT5 Sigma. Puma Biotechnology's average media sentiment score of 0.96 beat ALT5 Sigma's score of 0.38 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Puma Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ALT5 Sigma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Summary

Puma Biotechnology beats ALT5 Sigma on 10 of the 12 factors compared between the two stocks.

How does ALT5 Sigma compare to X4 Pharmaceuticals?

ALT5 Sigma (NASDAQ:AIFC) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

ALT5 Sigma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

X4 Pharmaceuticals has a net margin of -1,106.30% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

X4 Pharmaceuticals has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.91	-$344.51M	N/A	N/A
X4 Pharmaceuticals	$35.11M	10.85	-$79.20M	-$4.54	N/A

X4 Pharmaceuticals has a consensus target price of $9.38, suggesting a potential upside of 132.05%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, ALT5 Sigma had 4 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for ALT5 Sigma and 0 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.87 beat ALT5 Sigma's score of 0.38 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ALT5 Sigma	Neutral
X4 Pharmaceuticals	Very Positive

Summary

X4 Pharmaceuticals beats ALT5 Sigma on 11 of the 14 factors compared between the two stocks.

Get ALT5 Sigma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIFC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIFC vs. The Competition

Export

Metric	ALT5 Sigma	FIN Industry	Finance Sector	NASDAQ Exchange
Market Cap	$97.05M	$7.25B	$14.02B	$12.20B
Dividend Yield	N/A	5.88%	5.74%	5.66%
P/E Ratio	N/A	17.50	20.16	24.34
Price / Sales	3.91	11.78	148.67	135.34
Price / Cash	N/A	54.85	19.50	37.92
Price / Book	0.08	3.55	2.27	6.70
Net Income	-$344.51M	$300.94M	$1.14B	$337.21M
7 Day Performance	2.25%	2.69%	1.88%	1.78%
1 Month Performance	-30.95%	-0.95%	3.35%	3.65%
1 Year Performance	-92.69%	11.99%	12.98%	28.22%

ALT5 Sigma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIFC ALT5 Sigma	0.2933 of 5 stars	$0.69 -4.9%	N/A	-92.9%	$97.05M	$24.84M	N/A	170
BNTC Benitec Biopharma	1.7143 of 5 stars	$10.41 -3.7%	$27.00 +159.4%	-31.3%	$357.58M	$80K	N/A	20	Analyst Downgrade
SOPH SOPHiA GENETICS	2.4272 of 5 stars	$5.22 -3.3%	$7.50 +43.7%	+74.6%	$357.52M	$77.27M	N/A	520	Analyst Forecast
LRMR Larimar Therapeutics	3.6448 of 5 stars	$3.44 -1.7%	$15.29 +344.4%	+24.7%	$357.35M	N/A	N/A	30	News Coverage
PBYI Puma Biotechnology	1.4738 of 5 stars	$7.02 -0.4%	N/A	+111.0%	$357.32M	$228.40M	14.63	200	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIFC) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALT5 Sigma (AIFC) Competitors

AIFC vs. BNTC, SOPH, LRMR, PBYI, and XFOR

How does ALT5 Sigma compare to Benitec Biopharma?

Summary

How does ALT5 Sigma compare to SOPHiA GENETICS?

Summary

How does ALT5 Sigma compare to Larimar Therapeutics?

Summary

How does ALT5 Sigma compare to Puma Biotechnology?

Summary

How does ALT5 Sigma compare to X4 Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALT5 Sigma (AIFC) Competitors

AIFC vs. BNTC, SOPH, LRMR, PBYI, and XFOR

How does ALT5 Sigma compare to Benitec Biopharma?

Which has better earnings and valuation, BNTC or AIFC?

Is BNTC or AIFC more profitable?

Do analysts prefer BNTC or AIFC?

Do insiders and institutionals believe in BNTC or AIFC?

Which has more volatility & risk, BNTC or AIFC?

Does the media refer more to BNTC or AIFC?

Summary

How does ALT5 Sigma compare to SOPHiA GENETICS?

Do institutionals & insiders have more ownership in SOPH or AIFC?

Does the media favor SOPH or AIFC?

Do analysts prefer SOPH or AIFC?

Which has more volatility and risk, SOPH or AIFC?

Which has stronger earnings & valuation, SOPH or AIFC?

Is SOPH or AIFC more profitable?

Summary

How does ALT5 Sigma compare to Larimar Therapeutics?

Which has stronger valuation and earnings, AIFC or LRMR?

Does the media favor AIFC or LRMR?

Which has more risk and volatility, AIFC or LRMR?

Do analysts recommend AIFC or LRMR?

Do institutionals and insiders have more ownership in AIFC or LRMR?

Is AIFC or LRMR more profitable?

Summary

How does ALT5 Sigma compare to Puma Biotechnology?

Do analysts recommend AIFC or PBYI?

Is AIFC or PBYI more profitable?

Do institutionals and insiders have more ownership in AIFC or PBYI?

Which has stronger valuation and earnings, AIFC or PBYI?

Does the media favor AIFC or PBYI?

Which has more risk and volatility, AIFC or PBYI?

Summary

How does ALT5 Sigma compare to X4 Pharmaceuticals?

Which has more risk and volatility, AIFC or XFOR?

Is AIFC or XFOR more profitable?

Which has better earnings & valuation, AIFC or XFOR?

Do analysts rate AIFC or XFOR?

Do institutionals & insiders hold more shares of AIFC or XFOR?

Does the media prefer AIFC or XFOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools